Related Experiment Video
Updated: Apr 7, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
Andrew Stone1, Elena Zotenko1, Warwick J Locke1
11] Epigenetics Research Program, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia [2] Faculty of Medicine, St Vincent's Clinical School, UNSW, NSW 2052 &St Vincent's Hospital, Sydney, New South Wales 2010, Australia.
Abstract:
Expression of oestrogen receptor (ESR1) determines whether a breast cancer patient receives endocrine therapy, but does not guarantee patient response. The molecular factors that define endocrine response in ESR1-positive breast cancer patients remain poorly understood. Here we characterize the DNA methylome of endocrine sensitivity and demonstrate the potential impact of differential DNA methylation on endocrine response in breast cancer. We show that DNA hypermethylation occurs predominantly at oestrogen-responsive enhancers and is associated with reduced ESR1 binding and decreased gene expression of key regulators of ESR1 activity, thus providing a novel mechanism by which endocrine response is abated in ESR1-positive breast cancers. Conversely, we delineate that ESR1-responsive enhancer hypomethylation is critical in transition from normal mammary epithelial cells to endocrine-responsive ESR1-positive cancer. Cumulatively, these novel insights highlight the potential of ESR1-responsive enhancer methylation to both predict ESR1-positive disease and stratify ESR1-positive breast cancer patients as responders to endocrine therapy.
Insights
DNA methylation patterns in oestrogen receptor-positive breast cancer influence endocrine therapy response. Methylation changes at oestrogen-responsive enhancers can predict treatment outcomes and stratify patients for endocrine therapy.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Oestrogen receptor (ESR1) status guides endocrine therapy for breast cancer, but response is variable.
- Molecular determinants of endocrine response in ESR1-positive breast cancer are not fully understood.
Purpose of the Study:
- To investigate the role of DNA methylation in endocrine sensitivity in breast cancer.
- To identify methylation patterns associated with endocrine therapy response.
Main Methods:
- DNA methylome characterization of endocrine-sensitive breast cancer.
- Analysis of DNA methylation at oestrogen-responsive enhancers.
- Assessment of ESR1 binding and gene expression.
Main Results:
- DNA hypermethylation at oestrogen-responsive enhancers correlates with reduced ESR1 binding and gene expression, impairing endocrine response.
- ESR1-responsive enhancer hypomethylation is crucial for the transition to endocrine-responsive cancer.
- Differential DNA methylation impacts endocrine response in ESR1-positive breast cancers.
Conclusions:
- ESR1-responsive enhancer methylation is a key epigenetic mechanism affecting endocrine therapy response.
- DNA methylation patterns can potentially predict ESR1-positive breast cancer and stratify patients for endocrine therapy.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Master Transcription Regulators
Mitogens and the Cell Cycle
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

